Global Actinic Keratosis (AK) Treatment Market
Actinic Keratosis (AK) is a precancerous skin lesion that appear on areas of the skin damaged by chronic exposure to ultraviolet (UV) rays from the sun and/or indoor tanning. Solar keratosis is another name for the condition. The condition is typically characterized by rough, scaly patches on the skin caused by years of sun exposure. Actinic keratosis reflects abnormal skin cell development, due to DNA damage caused by short wavelength ultraviolet B (UVB) rays. Individuals working with polycyclic aromatic hydrocarbons (PAHs), such as coal or tar, are at a higher risk of getting AKs, as they are exposed to the UV rays for prolonged periods. A small percentage of actinic keratosis lesions have the potential to eventually culminate into a type of skin cancer, known as squamous cell carcinoma. Prevention of actinic keratosis is critically essential, as the condition usually precedes skin cancer. In case there are advanced lesions, skin biopsy is recommended for the diagnosis of AK and the eradication of highly invasive squamous cell carcinoma.
Increasing complications associated with actinic keratosis is expected to fuel the market development
The treatment of actinic keratosis as a part of preventive strategy for the reduction of interrelated disorders, such as non-melanoma skin cancer, squamous cell carcinoma, and basal cell carcinoma is coming to the forefront. According to the U.S. National Library of Medicine, 2015, approximately 60% of squamous cell carcinomas of the skin probably arise from actinic keratosis. Therefore, the rising incidences of skin cancers, such as intra epidermal squamous cell carcinoma, invasive cutaneous squamous cell carcinoma, basal cell carcinoma, and melanoma is expected to augment the market growth. Moreover, the wide presence and easy availability of generic drugs for the treatment for actinic keratosis is expected to boost the market growth. However, lack of medical awareness about the skin condition, available treatments, and delayed diagnosis are some of the factors restraining the global actinic keratosis market.
Request for Analysis of COVID-19 Impact on Actinic Keratosis Market – https://www.coherentmarketinsights.com/insight/request-pdf/1006
Global Actinic Keratosis (AK) Treatment Market Taxonomy
On the basis of treatment type, the global actinic keratosis treatment market is segmented into:
- Topical treatment
- 5-fluorouracil (5-FU) Cream
- Imiquimod Cream
- Diclofenac sodium gel
- Ingenol mebutate gel
- Surgical Procedures
- Curettage or Scrapping
- Laser Surgery
- Photodynamic therapy
The global actinic keratosis treatment market consists of various end users, inlcuding:
- Dermatologist Clinics
- Oncology Centers
- Ambulatory Surgical Centers
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/1006
Growing medical tourism in Asia Pacific is expected to facilitate the actinic keratosis market growth
Regional segmentation of the actinic keratosis market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to dominate the global actinic keratosis market, owing to the presence of innumerable treatment options in the region, development of combination therapies, and sequential actinic keratosis treatment assessed in clinical trials. According to the National Institute of Health, actinic keratosis is the second most common diagnosis made by dermatologists, with an estimated 5.2 million people in the U.S. visiting the physicians annually. Furthermore, Asia Pacific is expected to witness rapid growth actinic keratosis market, owing to the rapid medical tourism in India and China and the increasing focus of government to improve the healthcare facilities by developing efficacious non-invasive treatment for the condition.
Commitment of major market players to develop the effective photodynamic therapy projected to fuel the demand for AK treatment
The key players operating the global actinic keratosis market are DUSA Pharmaceuticals, Inc., Tolmar Pharmaceuticals, Inc., Perrigo Company Plc, Valeant Pharmaceuticals International, Inc., Aqua Pharmaceuticals, LLC, Galderma SA, LEO Laboratories, and Apotex. These companies are committed towards developing innovative products that can effectively manage skin conditions, such as actinic keratosis. For instance, actinic keratosis treatment with the Levulan Kerastick and BLU-U photodynamic therapy illuminator, with blue light illumination introduced by DUSA Pharmaceuticals, Inc., is indicated for the treatment of minimally to moderately thick actinic keratosis of the face or the scalp.
Got any Query? Feel free to ask us at: https://www.coherentmarketinsights.com/insight/talk-to-analyst/1006
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027